CLRO earnings analysis
What we found in CLRO's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
This 10-Q extract does not provide quarterly revenue, margins, EPS, balance-sheet figures or cash-flow data, so operating performance versus the prior period and prior year cannot be assessed from the filing information supplied. The company states that continuing activities are not expected to generate material revenue sufficient to fund ongoing operating costs, leaving reliance on the merger, financing or additional capital. Key negatives are the $2,500,000 Nasdaq equity deficiency, the July 8, 2026 change-of-control listing requirement, potential failure of the merger within 180 days, and substantial dilution from 12,500,000 consideration shares plus up to 855,000 advisor shares.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Disclosure controls remained effective
- Management concluded that disclosure controls and procedures were effective as of June 30, 2026, and reported no changes during the quarter that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
- Nasdaq compliance plan submitted
- The company submitted a Nasdaq compliance plan on May 22, 2026 after receiving an April 7, 2026 notice regarding the $2,500,000 stockholders’ equity requirement under Nasdaq Rule 5550(b)(1).
- Merger transaction remains active
- The proposed merger includes 12,500,000 consideration shares and up to 855,000 advisor shares, representing approximately 82% of common stock on a pro forma basis before the financing.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Nasdaq delisting risk increased
- Nasdaq notified the company on April 7, 2026 that it was not compliant with the $2,500,000 minimum stockholders’ equity requirement. Separately, on July 8, 2026, Nasdaq determined the merger is a change of control requiring the post-transaction entity to satisfy initial listing requirements, creating a material delisting risk.
- Merger and financing may fail
- The merger and financing are subject to conditions including stockholder approval, Vivani approval, financing completion, Form S-1 effectiveness and Nasdaq approval. The merger may be terminated if it is not completed within 180 days of signing, and failure to complete it would leave substantial doubt about the company’s ability to continue as a going concern.
- Limited operations and substantial dilution
- The company states that continuing activities are not expected to generate material revenue sufficient to fund ongoing operating costs. The proposed transaction would issue 12,500,000 consideration shares and up to 855,000 advisor shares, approximately 82% of common stock before financing, while Vivani would hold a majority of voting power.
- Integration and assumed-liability risk
- The merger would make the company responsible for Cortigent’s legal, financial, regulatory and compliance obligations, including potentially unknown or contingent liabilities. Management identifies integration difficulties such as diversion of attention, systems and personnel integration, and increased expenses that could reduce revenues, earnings and cash flows.
- Nevada reincorporation changes governance risk
- The company completed reincorporation from Delaware to Nevada on April 22, 2026. Management notes that Nevada law differs from Delaware law regarding stockholder rights, director and officer fiduciary duties, and anti-takeover provisions.
- Change of control and voting concentration
- Following the merger, existing stockholders would have limited influence because Vivani will designate the CEO, CFO and 4 of 5 directors. Stockholders holding at least 50.1% entered voting support agreements, and the largest stockholder and affiliates holding approximately 61% already approved the share issuance.
What they said about what is next.
The 10-Q does not provide quantitative revenue or EPS guidance. Management states that continuing activities are not expected to generate material revenue sufficient to fund ongoing operating costs, but no numeric outlook is disclosed.
The filing reads worse than the one before it.
What came before.
- 10-Q · May 15, 2026
- ClearOne, Inc.'s Q1 2026 report reflects a significant transition following the asset sale in October 2025, resulting in minimal revenue from continuing operations. The company reported a net loss of $487,000, a…
- 10-K · March 31, 2026
- ClearOne completed an Asset Sale on October 24, 2025 for gross cash consideration of $3.0 million and has transitioned to a transitional posture where it no longer manufactures or sells products and continuing…
- 10-Q · November 14, 2025
- ClearOne, Inc. reported a challenging third quarter for the period ending September 30, 2025, with significant losses both on the income statement and in cash flows, as the company continues its restructuring amid asset…
- 10-Q · August 14, 2025
- ClearOne, Inc. reported a decline in total revenues to $1.92 million for Q2 2025, down from $2.30 million in Q2 2024, contributing to a deepening net loss of $4.57 million vs. a loss of $2.82 million last year. The…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing CLRO makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever